The function of the Clinical Core is to insure that the clinical aspects of the studies are conducted in an efficient and effective manner. The core will insure that each of the participating Institutions have up to date clinical protocols, that patients are registered onto studies prior to the initiation of the studies, and that all patients are eligible for the studies on which they are studied and treated. Another function of this Core is to insure that the clinical data necessary for the proposed studies is obtained and provided to the Biostatistical Core in a timely manner. The Core will also insure that clinical specimens are obtained at the appropriate time and transported to the Core Laboratory for processing, distribution, and storage. The members of this Core will be in constant contact with the appropriate individuals at the collaborating Institutions to insure that all of the studies and specimen collections are proceeding without difficulty. The Core will also apply uniform criteria for all diagnoses and for all treatment outcome evaluation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA075606-05
Application #
6459011
Study Section
Project Start
2001-06-07
Project End
2003-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
2001
Total Cost
$312,755
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Raza, A; Candoni, A; Khan, U et al. (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45:2099-104
Candoni, Anna; Silvestri, Federico; Buonamici, Silvia et al. (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 41:13-20
Raza, Azra; Buonamici, Silvia; Lisak, Laurie et al. (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28:791-803
Huang, X K; Meyer, P; Li, B et al. (2003) The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro. Leuk Lymphoma 44:157-64
Gladstone, Betty; Sivaraman, Smitha; Galili, Naomi et al. (2003) A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. Leuk Res 27:529-37
Reddy, Poluru L; Shetty, Vilasini T; Dutt, Diya et al. (2002) Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol 116:564-75
Allampallam, Krishnan; Shetty, Vilasini; Mundle, Suneel et al. (2002) Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 75:289-97
Shetty, Vilasini; Hussaini, Seema; Alvi, Sairah et al. (2002) Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients. Br J Haematol 116:817-25
Zorat, F; Shetty, V; Dutt, D et al. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115:881-94
Preisler, H D (2001) Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. Cancer Treat Res 108:185-230

Showing the most recent 10 out of 40 publications